📰 Guy Goodwin News
Page 3 - Guy Goodwin News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Guy Goodwin. Real-time updates on events, politics, business and more.
July 24, 2023
If successful, they could herald a new era for treating anorexia, which has the highest mortality rate of any psychiatric condition (more than 5 per cent, reported JAMA Psychiatry in 2011).
July 24, 2023
Self-reported responses from the patients revealed that 90% regarded the psilocybin treatment as meaningful and positive, endorsing additional treatments if available.
July 24, 2023
A single dose of the psychedelic, given alongside psychological support, is a safe and acceptable treatment for the condition, a study suggests.
July 18, 2023
COMPASS Pathways (NASDAQ: CMPS) shared results from an open-label Phase 2 trial assessing its synthetic psilocybin COMP360 alongside SSRIs for Treatment-Resistant Depression (TRD.)
July 13, 2023
13.07.2023 - Leading psychiatrists and researchers examine common assumptions about the term “psychedelic-assisted psychotherapy” and the role of psychotherapy when evaluating psilocybin treatment.Authors highlight the need for clarity in terminology and ... Seite 1
May 30, 2023
Largest ever trial of psilocybin offers hope of treatment to cancer patients with major depressive disorder
May 30, 2023
The research conducted at Cedar Clinical Research in Draper is part of the first ever phase 3 program of psilocybin therapy, and the largest of its kind VANCOUVER, BC, May 30, 2023 /PRNewswire/ -... | May 30, 2023
May 30, 2023
Numinus Wellness Inc. (TSX:NUMI, OTC:LKYSF) said its wholly-owned subsidiary Cedar Clinical Research (CCR) has begun studying COMP360 psilocybin therapy, an...
May 26, 2023
More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological supportOpen label phase 2 study,... | May 26, 2023
May 26, 2023
More than half of the patients demonstrated remission of depression at 18 months, after a single dose of 25mg investigational COMP360 psilocybin with psychological supportOpen label phase 2 study, conducted